Abstracts tagged "immunoproteasome"

Abstract Number: 2530 • ACR/ARP Annual Meeting 2019
Safety, Pharmacokinetics, and Pharmacodynamics of a Lyophilized Drug Product of KZR-616, a Selective Inhibitor of the Immunoproteasome
Ben Snyder ¹, Darrin Bomba ², Ken Harvey ², Janet Anderl ², Christopher Kirk ², Jinhai Wang ², R Andrea Fan ² and Niti Goel³, ¹Nucleus Network Pty Ltd, Melbourne, Australia, ²Kezar Life Sciences, SOUTH SAN FRANCISCO, CA, ³Kezar Life Sciences, Duke University School of Medicine, South San Francisco, CA
Background/Purpose: KZR-616, a first-in-class selective inhibitor of the immunoproteasome, is being evaluated for the treatment of multiple autoimmune diseases, including LN and PM/DM. At 30…